AATS/ISHLT Guidelines on Selected Topics in Mechanical Circulatory Support

Published 23 January 2020

Editors: James K. Kirklin, Francis D. Pagani, Daniel J. Goldstein, Ranjit John, Joseph G. Rogers
Contributing Authors: Pavan Atluri, Francisco A. Arabia, Anson Cheung, William Holman, Charles Hoopes, Valuvan Jeevanandam, Ranjit John, Ulrich P. Jorde, Carmelo A. Milano, Nader Moazami, Yoshifumi Naka, Ivan Netuka, Francis D. Pagani, Salpy V. Pamboukian, Sean Pinney, Joseph G. Rogers, Craig H. Selzman, Scott Silverstry, Mark Slaughter, John Stulak, Jeff Teuteberg, Juliane Vierecke.
Reviewers: Stephan Schueler, MD, PhD, FRCS; David A. D'Alessandro, MD

J Heart Lung Transplant. Mar 2020;39(3):187-219

• Advanced Heart Failure & Transplantation
• Cardiology
• Cardiothoracic Surgery
• Joint Statement
• Mechanical Circulatory Support
• Professional Guideline
• Publications & Journals
• Standards & Guidelines

Mechanical circulatory support (MCS) evolved from an engineering dream to clinical reality during the 1980s when increasing numbers of patients were dying on heart transplant wait lists. Following the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure Trial, the US Food and Drug Administration (FDA) approved a pulsatile implantable left ventricular assist device (LVAD) for long-term implantation in 2002. When the FDA approved the first US continuous flow (CF) LVAD in 2008, the landscape had changed dramatically. With demonstrated survival on device exceeding 80% at 1 year, implants in the United States progressively increased to nearly 3000 per year. With the maturation of this field, guidelines for patient care and decision making have become more evidenced-based.

Developed by a writing committee of 25 surgeons and 10 cardiologists, this consensus guidelines document focuses on selected topics in patient management.

Read at JHLT